Genomictree Inc.
228760
株式のランク
#19175
Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to... Genomictree Inc. is a molecular diagnostics firm that harnesses biomarkers to develop and market advanced detection tools for both oncological conditions and various infectious diseases. Its product line includes EarlyTect C, a screening solution for the early identification of colorectal cancer. For lung cancer, it offers EarlyTect L, which targets epigenetic markers in patients with pulmonary nodules, and for bladder cancer, EarlyTect B, designed to detect specific genetic and epigenetic markers in individuals with hematuria. The company also provides a range of companion diagnostics: AccuraTect-KRAS and AccuraTect-BRAF assist in colorectal cancer management, while AccuraTect-EGFR supports lung cancer treatment. In addition, Genomictree supplies AccuraDTect SARS-CoV-2 RT-qPCR kits for infectious disease testing, and offers its technologies to support various diagnostic test providers. Founded in 2000, the company is based in Daejeon, South Korea.
株価
$6.61
時価総額
$162.26M
変化（1日）
1.06%
変化（1年）
-50.87%
国
KR
取引 Genomictree Inc. (228760)
カテゴリー
Healthcare
の時価総額 Genomictree Inc.(228760)
時価総額: $162.26M
October 2026時点で、Genomictree Inc. の時価総額は $162.26M です。これは、当社のデータによると、Genomictree Inc. が世界で19175th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Genomictree Inc. の時価総額の履歴（2017 から 2026 まで）
